1-Acetyl-2-phenylhydrazine carcinogenesis in mice. by Toth, B.
Br. J. Cancer (1979) 39, 584
Short Communication
1-ACETYL-2-PHENYLHYDRAZINE CARCINOGENESIS IN MICE
B. TOTH
From the Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha,
Nebraska 68105, U.S.A.
Received 22 November 1978 Accepted 22 January 1979
To DATE, 40 hydrazines, hydrazides
and hydrazones have been shown to be
cancer-inducing substances in laboratory
animals (Toth, 1975 and submitted).
These studies appear important from an
environmental viewpoint since many of
these chemicals are extensively used in
industry, agriculture and medicine (The
Merck Index 1976). Furthermore, several
occur naturally in edible mushrooms and
in tobacco (Levenberg, 1960; List and
Luft, 1968; Liu et al., 1974).
In a recent study, it was shown that
phenylhydrazine (PHZ) HCI, used in
medicine as a drug against polycythaemia
vera, induced blood-vessel tumours in
mice (Toth & Shimizu, 1976). In an earlier
experiment, PHZ.HC1, when fed by stom-
ach tube, produced lung tumours in mice
(Clayson et al., 1966). The present investi-
gation was initiated because PHZ therapy
in man has produced many undesirable
side effects and was subsequently replaced
by 1-acetyl-2-phenylhydrazine (APH).
The work described demonstrates the
tumorigenicity of APH administered con-
tinuously in drinking water at the maxi-
mum tolerated dose for the lifespan of
Swiss mice.
Swiss albino mice from the colony
randomly bred by us since 1951 were used.
They were housed in plastic cages with
granular cellulose bedding, were separated
K NH-NH- CO- CH3
FIG. Chemical structure of 1-acetyl-2-phenyl-
hydrazine.
according to sex in groups of 10, and were
given Wayne Lab-Blox diet in regular
pellets (Allied Mills, Inc., Chicago, Ill.) and
tapwater or the chemical solution ad
libitum as described below.
The chemical used was I-acetyl-2-
phenylhydrazine (APH, pyrodin, Fig. 1)
mol. wt 150-18, m.p. 128-50C, 99% pure,
was obtained from Eastman Kodak Co.,
Rochester, N.Y. After 48 h standing at
room temperature, the 0-015% APH solu-
tion that was used for the long-term
experiment was analysed by gas chroma-
tography and found to contain more than
97% APH unchanged.
Toxicity studies were carried out with
APH before the long-term experiment.
Seven dose levels of APH (1, 0 5, 0-25,
0-125, 0-062, 0-031 and 0-015%) were
administered in the drinking water for 35
days to Swiss mice. When 4 parameters-
survival rates, body weights, chemical
consumption figures and histological
changes-were taken into account, the
0.015% dose level was found to be suitable
for the lifelong treatment. This toxicity
technique was developed in this laboratory
(Toth, 1972).
The solutions were prepared x 3 weekly
and the total consumption of water con-
taining APH was measured at the same
intervals during the treatment period. The
solutions were contained in brown bottles
because of the possible light sensitivity of
the chemical. The chronic experimental
groups and the controls were as follows:
Group 1. APH was dissolved in the
drinking water as a 0.015% solution and
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50 male mice that were 6 weeks (43 days)
old at the beginning of the experiment.
The average daily consumption of water
containing APH per animal was 9-5 ml
for females and 11-7 ml for males, making
the average daily intake of APH 1-4 mg
for a female and 1 8 mg for a male.
Group 2. As an untreated control, 100
female and 100 male mice were kept and
observed from 6 weeks of age.
The experimental and control animals
were carefully checked and weighed at
weeklyintervals, andthegrosspathological
changes were recorded. The animals were
allowed to die or were killed with ether
when found in poor condition. Complete
necropsies were performed on all animals.
All organs were examined macroscopically
and were fixed in 10% buffered formalin.
Histological studies were done on the liver,
spleen, kidney, bladder, thyroid, heart,
pancreas, testis, brain, nasal turbinale,
and at least 4 lobes of the lungs of each
mouse, as well as on other organs showing
gross pathological changes. Sections from
these tissues were stained routinely with
haematoxylin and eosin.
The survival rates after weaning are
recorded in Table I. As can be seen from
the data, the treatment significantly
shortened the survival in females but not
in males.
The number, percentages of animals
with tumours, and their ages at death are
summarized in Table II. The treatment
gave rise to significant incidences ofblood-
vessel tumours which are described in
detail below.
Blood-vessel tumours.-Of the treated
females, 16 (32%) developed such neo-
plasms, of which 8 were classified as
angiomas and the remaining 8 as angio-
sarcomas. With the exception of 2 angio-
sarcomas which occurred in liver and
spleen, all the others were seen only in
the liver. Of the treated males, 12 (24%)
developed vascular tumours, of which 7
were classified as angiomas and the re-
maining 5 as angiosarcomas. Six angiomas
occurred in livers and 1 in the spleen, while
2 angiosarcomas were in livers and the
remaining 3 in livers and spleen.
Ofthe untreated control females, 8 (8%)
developed such tumours. Of these, 4 were
classified as angiomas and the remaining
4 as angiosarcomas. The tissue distribution
of angiomas was: liver, 2; ovary, 2; while
the angiosarcomas were: liver, 2; uterus,
1; lymph node, 1. Of untreated males, 5
(5%) developed vascular-tissue tumours.
Ofthese, 3 were angiomas and the remain-
ing 2 were angiosarcomas. The tissue dis-
tribution of angiomas was: liver, 2; anal
gland 1, while the angiosarcomas were:
liver, 1; pararenal fat, 1.
Macroscopically and histologically the
blood-vessel tumours were similar to those
described earlier in this laboratory (Toth
and Wilson, 1971; Toth & Malick, 1976).
Other tumours. A few other types of
neoplasms were also found as shown in
Table II. Since their incidence was low,
they could not be attributed to the treat-
ment. On the other hand, in the treated
groups the incidences of some of the spon-
taneous tumours were lower than of those
in the corresponding controls. Part of
these differences were due to the lower
survival rates of the treated mice, while
the remaining part could not be substan-
tiated statistically.
Statistical analysis was carried out
TABLE I.-Treatment and survival rates in I-acetyl-2-phenylhydrazine (APH)-treated and
control Swiss mice
Group Treatment
1 0-015% APH in
drinking water
daily for life
2 Untreated
controls
Initial
no. and
sex
50Y
50&,
No. of survivors (age in weeks)
10 20
50 48
50 48
30
41
42
40
38
40
50
37
33
60
31
29
70
28
24
80
18
9
90 100 110 120 130
9 5 3 -
6 .2 1 -
100o 100 100 99 96 96 91 78 66 45 28 13 2 -
100d 100 98 92 88 80 62 36 17 11 3 2 1 -
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TABLE II.-Tumour distribution in I-acetyl-2-phenylhydrazine (APH)-treated and control
Swiss mice
Animals with tumours of
Group Treatment
1 0-015% APH
in drinking water
daily for life
2 Untreated
controls
Effective
no. and
Blood vessels
Age at
death*
sex No % (wks) Other organst
49Y 16 32 79 (56-111) 5 Adenomas of lungs (78, 82, 85, 93, 114)
4 Malignant lymphomas (54, 60, 75, 79)
1 Osteoma (83)
50, 12 24 73 (47-112) 4 Adenomas of lungs (55, 74, 80, 112)
1 Adenoma and 1 adenocarcinoma of lungs (41)
1 Hepatoma (55)
1 Osteoma (90)
1 Malignant lymphoma (65)
100,y 8 8 92 (74§119) 20 Malignant lymphomas (31, 33, 47, 76, 79,
85, 86, 87, 89, 89, 91, 91, 94, 99, 102, 103,
104, 111, 114, 116)
9 Adenomas of lungs (68, 68, 88, 104, 105, 106,
110, 110, 116)
5 Adenocarcinomas of lungs (78, 84, 84, 88, 99)
1 Adenoma and adenocarcinoma of lungs (67)
2 Fibrosarcomas, subcutaneous (101, 102)
2 Sex-cord mesenchyma tumours (107, 114)
1 Adenoacanthoma of ovary (71)
1 Adenoma of ovary (110)
1 Adenoma of thyroid (88)
1 Adenocarcinoma of breast (127)
1 Adenocarcinoma of duodenum (86)
1 Carcinoma of glandular stomach (64)
100l 5 5 75 (57§92) 16 Adenomas of lungs (40, 40, 43, 59, 59, 61, 63,
64, 65, 67, 69, 74, 78, 94, 104, 124)
5 Adenocarcinomas of lungs (60, 62, 69, 77, 84)
1 Adenoma and adenocarcinoma of lungs (80)
8 Malignant lymphomas (28, 62, 67, 78, 84, 91,
92, 112)
2 Fibrosarcomas, subcutaneous (69, 92)
2 Adenomas of thyroids (63, 92)
2 Hepatomas (68, 94)
1 Adenoma of parathyroid (78)
* Average and range.
t Age at death in parentheses.
using Fisher's exact test for 2x 2 tables
(Armitage, 1971), and demonstrated that
in females (P<0 0004) and males (P<
0.0016) the blood-vessel tumour incidence
was significantly higher in the treated
groups. Histopathological examination
showed the characteristic appearances of
angiomas and angiosarcomas of blood
vessels.
I-Acetyl-2-phenylhydrazine is em-
ployed in medicine for the treatment of
polycythaemia vera and for its antipyretic
action (The Merck Index, 1976). Earlier,
phenylhydrazine hydrochloride was ad-
ministered orally, in a 0-2 g daily dose to
combat polycythaemia vera, for a few
days, until certain complications ensued,
when half the dose was given for several
weeks. The untoward symptoms included:
jaundice, nausea, bladder irritation, ec-
zema, erythema (Sollmann, 1957). Sub-
sequently, to eliminate some of the un-
desirable side effects, an acetyl-group was
attached to the phenylhydrazine molecule.
In the present experiment I-acetyl-2-
phenylhydrazine induced blood-vessel tu-
mours in mice. The therapeutic value of
this drug in man should be considered
in conjunction with its tumorigenicity
in animals, and obviously a risk/benefit
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evaluation should be made concerning its
future use.
This investigation is part of our study
ofthe carcinogenic nature ofthe hydrazine
series of compounds. These studies began
with a demonstration of the carcino-
genicity of the antituberculosis drug-
isonicotinic acid hydrazide (Juhasz et al.,
1957). This finding was followed by
numerous other investigations into syn-
thetic hydrazines widely found in the
environment and to which the human
population is exposed to a considerable
degree (Biancifiori & Ribacchi, 1962;
Druckrey et al., 1967; Colvin, 1969;
Juchau & Horita, 1972; IARC Monographs
on the Evaluation of Carcinogenic Risk of
Chemicals to Man, 1974; LaRue, 1977).
The field recently received additional
attention when the various naturally
occurring hydrazine ingredients of the
edible mushrooms Aqaricus bisporus
(Levenberg, 1960) and Gyromitra esculenta
(List and Luft, 1968) and tobacco (Liu
et al., 1974) were also shown to cause
cancer in laboratory animals (Toth, 1973;
Toth & Nagel, 1978; Toth et al., 1978).
Finally, a group of hydrazines has been
under study for a possible relationship
between chemical structure and induced
tumouLr types and incidences (Toth, 1979).
I wish to thank Dr Kashiinath Patil for the statis-
tical analysis and Mr James Erickson for the experi-
mental work. This study was supported by USPHS
contract NO1 CP33278 from the National Cancer
Institute, NIH.
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